Skip to content
OpenCapital
Get started

BioCryst Pharmaceuticals BCRX Royalty Financing Liabilities

Other financials

Income statement

See full
Revenue$156.4M+7.5%
Gross profit$151.0M+7.1%
Operating income-$701.6M-3,405%
Net income-$721.8M-2,255,763%
EPS (diluted)-$2.98—

Balance sheet

See full
Cash & equivalents$173.4M+62.2%
Total debt$411.8M+24.7%
Total equity-$553.8M-22.6%
Total assets$465.1M-3.1%

Cash flow

See full
Operating cash flow-$61.8M-125%
CapEx$403.0K+182%
Free cash flow-$62.2M-125%

Valuation

See full
Market cap$2.37B+52.3%
Enterprise value$2.6B+46.7%
P/S2.7×-0.4×

Profitability

See full
Gross margin97.8%+0.8pp
Operating margin-43.1%-49.7pp
Net margin-51.7%-69.7pp
FCF margin35%—

Returns & leverage

See full
Return on equity-882.8%—
Debt / equity0.1×—
Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:RoyaltyFinancingLiabilities.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's royalty financing liabilities.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BioCryst Pharmaceuticals's royalty financing liabilities?
BioCryst Pharmaceuticals (BCRX) reported royalty financing liabilities of $447.5M in Q1 2026.
How has BioCryst Pharmaceuticals's royalty financing liabilities changed year-over-year?
BioCryst Pharmaceuticals's royalty financing liabilities decreased by 10.7% year-over-year, from $500.92M to $447.5M.
What is the long-term trend for BioCryst Pharmaceuticals's royalty financing liabilities?
Over 2 years (2023 to 2025), BioCryst Pharmaceuticals's royalty financing liabilities has grown at a -6.4% compound annual growth rate (CAGR), from $531.6M to $465.69M.